Replies to post #68068 on Biotech Values

[DewDiligence]

AZN – The JUPITER trial is having a material effect on Crestor sales, evidently. Worldwide 1Q09 sales of Crestor were $969M, +35% year-over-year in local currencies.

Crestor’s TRx share in the US anti-cholesterol market rose to 10.3% in March 2009, and Crestor is the only statin that is gaining US market share.

Source: http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q1-2009/AZN-Q1-results-09-Narrative.pdf